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Abstract 
Background: The 90‑kDa heat‑shock protein (Hsp90) from Nicotiana benthamiana (NbHsp90.3) is a promising adju‑
vant, especially for those vaccines that require a T cell‑mediated immune response. Toxoplasma gondii SAG1 is consid‑
ered one of the most important antigens for the development of effective subunit vaccines. Some epitopes located in 
the SAG1 C‑terminus region have showed a strong humoral and cellular immune response. In the present study, we 
aimed to assess the efficacy of NbHsp90.3 as carrier/adjuvant of SAG1‑derived peptide  (SAG1HC) in a T. gondii infection 
murine model.
Methods: In the present study, C57BL/6 mice were intraperitoneal immunized with the NbHsp90.3‑SAG1HC fusion 
protein (NbHsp90.3‑SAG1HC group), mature SAG1 (SAG1m group), NbHsp90.3 (NbHsp90.3 group) or PBS buffer 1× 
(PBS group). The levels of IgG antibodies and the cytokine profile were determined by ELISA. Two weeks after the last 
immunization, all mice were orally challenged with 20 cysts of T. gondii Me49 strain and the number of brain cysts 
was determined. In addition, both humoral and cellular immune responses were also evaluated during the acute and 
chronic phase of T. gondii infection by ELISA.
Results: The characterization of the immune response generated after vaccination with NbHsp90.3 as an adjuvant 
showed that NbHsp90.3‑SAG1HC‑immunized mice produced antibodies that were able to recognize not only rSAG1m 
but also the native SAG1 present in the total lysate antigen extract  (SAG1TLA) from T. gondii tachyzoites, while con‑
trol groups did not. Furthermore, anti‑rSAG1m IgG2a/2b antibodies were significantly induced. In addition, only the 
spleen cell cultures from NbHsp90.3‑SAG1HC‑immunized mice showed a significantly increased production of IFN‑γ. 
During the chronic phase of T. gondii infection, the antibodies generated by the infection were unable to detect the 
recombinant protein, but they did react with TLA extract. In addition, splenocytes from all groups showed a high pro‑
duction of IFN‑γ when stimulated with rGRA4, but only those from NbHsp90.3‑SAG1HC group stimulated with rSAG1m 
showed high production of IFN‑γ. Finally, NbHsp90.3‑SAG1HC‑immunized mice exhibited a significant reduction in the 
cyst load (56%) against T. gondii infection.
Conclusions: We demonstrated that NbHsp90.3 enhances the humoral and cell‑mediated immune response 
through a Th1 type cytokine production. Mice vaccinated with NbHsp90.3‑SAG1HC exhibited a partial protection 
against T. gondii infection and it was correlated with the induction of memory immune response. We developed and 
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Background
SAG1 is present in tachyzoites of T. gondii parasites. This 
protein is a stage-specific protein, which presents low 
polymorphism between different T. gondii strains and 
elicits a strong specific antibody response [1, 2]. SAG1 
is able to stimulate the production of IFN-γ of T cells in 
seropositive individuals [3]. For this reason, this antigen 
has been suggested as an excellent candidate for vaccine 
development in the prevention of toxoplasmosis.
In several studies, SAG1 has been used as a native-
purified protein, recombinant protein or DNA expression 
vector in the development of vaccines against T. gondii 
[4, 5]. Likewise, various peptides of SAG1 have demon-
strated to stimulate host humoral and cellular immu-
nity and to provide partial protection against T. gondii 
[6]. The selection of proper epitopes becomes necessary 
to eliminate deleterious components and to retain the 
advantageous elements in the design of an efficient and 
safe vaccine [7, 8]. Therefore, many studies have identi-
fied different short peptides present in SAG1 that would 
have promising immunogenic properties and could be 
used in the development of acellular vaccines [9–12]. 
Wang et al. [11] showed that peptides of SAG1 contain-
ing B-cell epitopes are highly immunogenic. In addition, 
Godard et al. [9] observed that the C-terminus of SAG1 
is the dominant antigenic and immunogenic region and, 
in particular, the  SAG1238–256 peptide is an important 
T-cell epitope. Likewise, Siachoque et al. [10] scanned the 
B-cell epitopes present in SAG1 and revealed that they 
are primarily placed near the C-terminus. Furthermore, 
Cardona et  al. [11] found that B-cell epitopes of SAG1 
enclosed in the  SAG1301–320 position show the highest 
reactivity against human sera from T. gondii-infected 
patients.
Another important aspect in the development of acel-
lular vaccines is the selection of the appropriated adju-
vant, since it plays an important role in the efficacy of the 
immunizations. It is generally accepted that a T helper 
1 (Th1) response associated with IFN-γ producing cells, 
is the main mediator of the immunity against T. gondii 
infection [13, 14]. Therefore, Hsp90s and Hsp70s have 
been used as antigen/carriers in order to induce B- and 
T-cell mediated immune responses [15–19]. Our group 
showed that plant Hsp90s (pHsp90s) are B cell mito-
gens and that the presence of toll-like receptor 4 (TLR4) 
is necessary for a suitable response [18]. In addition, 
our results showed that pHsp90s could be incorporated 
as adjuvants in a vaccine formulation that needs a Th1-
mediated response along with the stimulation of cyto-
toxic  CD8+ cells to confer immunity [19].
Previously, we expressed SAG1 fused to Leishmania 
infantum 83-kDa heat-shock protein (LiHsp83-SAG1) 
to improve the stability of the recombinant protein when 
expressed in plants [20]. In addition, oral immunization 
with plant-made LiHsp83-SAG1 produced a significant 
reduction of the cyst load and this correlated with an 
increment of specific antibodies anti-rSAG1 [20]. A fur-
ther advantage of employing Hsp90 as adjuvants/carri-
ers is the possibility of using peptides containing B- and 
T-cell epitopes, instead of the full-length antigen or large 
polypeptides that may enclose toxic or unstable regions 
that can affect their correct expression in a heterolo-
gous system. While LiHsp83 is a pathogenic-associated 
adjuvant, pHsp90s offers the advantage of being a non-
pathogenic adjuvant. Bearing this in mind, we character-
ized the role of pHsp90 in the modulation of the immune 
response. Thus, we evaluated the efficacy of Nicotiana 
benthamiana Hsp90.3 (NbHsp90.3) as a carrier/adjuvant 




A peptide of Toxoplasma gondii SAG1  (SAG1HC) (from 
residue 221 to residue 319 of the protein) that encodes 
both T- and B-cell epitopes [10] was amplified by PCR 
using the plasmid pRSET-A-SAG177–322 as a template 
[21]. The forward primer sequence was 5′-ggt acc ATA 
AAG TTC CTC AAG ACA AC-3′ and the reverse primer 
sequence was 5′-aag ctt CTA AAT GGA AAC GTG ACT 
GGC-3′ flanked by KpnI and HindIII restriction sites 
(lowercase), respectively. The N. benthamiana Hsp90.3 
full length sequence (NbHsp90.3) was amplified by PCR 
using the plasmid pRSET-A-NbHsp90.3 as a template 
[18]. The forward degenerated primer sequence was 
5′-gga tcc ATG GCG GAS GCA GAR ACS TTT GCW 
TTY CAA GC-3′ and the reverse primer sequence was 
5′-ctc gag GTC TAC TTC CTC CAT CTT TTC AGC 
ATC ATC AGC-3′ flanked by BamHI and XhoI restric-
tion sites (lowercase), respectively. The PCR products 
were first cloned separately into pGEM-T easy vectors 
(Promega, Fitchburg, WI, USA). After sequencing, the 
isolated segments were sequentially cloned into pRSET-A 
validated a vaccine formulation which, to our knowledge, for the first time includes the NbHsp90.3 protein covalently 
fused to a peptide from T. gondii SAG1 protein that contains T‑ and B‑cell epitopes.
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(Invitrogen, Carlsbad, CA, USA) to construct pRSET-A-
NbHsp90.3-SAG1HC expression vector.
Expression and purification of recombinant proteins
The pRSETA-NbHsp90.3-SAG1HC plasmid was trans-
formed in Escherichia coli BL21  Star™(DE3) compe-
tent cells (Invitrogen). Bacteria were cultured to an 
optical density of 0.5 (absorbance at 600  nm) and then 
protein expression was induced with isopropyl-β-d-
thiogalactoside (IPTG) to a final concentration of 1 mM 
for 4 h. Cells were harvested by centrifugation and stored 
at -20 °C until use.
Soluble NbHsp90.3-SAG1HC protein was purified 
under non-denaturing conditions using a nitrilotriacetic 
acid-Ni2+ column (Qiagen, Germantown, MD, USA) 
[18]. Recombinant NbHsp90.3 protein was expressed in 
E. coli Rosetta strain (Invitrogen) and was purified as in 
Corigliano et al. [18]. Recombinant SAG1m  (SAG177–322) 
protein was expressed in E. coli and it was purified as in 
Laguía Becher et  al. [21]. After purification, NbHsp90.3 
(84.5-kDa), SAG1m (34-kDa) and NbHsp90.3-SAG1HC 
(96-kDa) were passed through a polymyxin B agarose 
resin and then the LPS concentration was measured as 
previously described by Corigliano et al. [18].
SDS‑PAGE and Western blot analysis
Purified recombinant proteins were separated by SDS-
PAGE (10%) using the Mini-Protean system III (Bio-Rad, 
Hercules, CA, USA) and stained with Coomassie Brilliant 
Blue. For Western blot analysis, recombinant proteins 
were transferred onto PVDF membranes (GE Healthcare, 
Chicago, IL, USA) using an Electro Transfer Unit (Bio-
Rad). The membranes were incubated with either mouse 
anti-6xHIS monoclonal antibody (1:1000; Cell Signal-
ing Technology Inc., Danvers, MA, USA), mouse poly-
clonal antibodies against rSAG1m (1:1000) or sera from 
NbHsp90.3-SAG1HC immunized mice (1:100) as pri-
mary antibodies. Then, membranes were incubated with 
alkaline phosphatase conjugated goat anti-mouse IgG 
(1:5000, Sigma, St. Louis, MO, USA). The reaction was 
developed by the addition of nitroblue tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP, Pro-
mega) substrate.  PageRuler™ Prestained Protein Ladder 
(Fermentas, Waltham, MA, USA) was used as molecular 
marker.
Preparation of the total lysate antigens (TLA) 
from Toxoplasma gondii tachyzoites
TLA were obtained from a suspension of T. gondii RH 
tachyzoites. RH tachyzoites were sonicated (10  s pulse 
ON with 30  s intervals OFF, for 1 min) using a 130  W 
ultrasonic processor (Vibra  Cell™; Sonic, Newtown, CT, 
USA) and centrifuged at 8000× g for 5 min at 4 °C. Then, 
the supernatant was quantified by Bradford protein assay 
and stored at -80 °C until use.
Mice and vaccination
C57BL/6 (H-2b) mice specific-pathogen-free were 
obtained from the central bioterium of Facultad de Cien-
cias Exactas y Naturales of Universidad de Buenos Aires. 
Six- to eight-week-old female mice were bred and housed 
following the institutional guidelines of the Universi-
dad de General San Martín (C.I.C.U.A.E., IIB-UNSAM, 
09/2016). Mice had access to food and water ad libitum 
and were maintained at 21–22  °C, 12:12  h light-dark 
photocycle. Five to eight mice per group were intraperi-
toneally immunized with equimolar amount of SAG1m 
(34-kDa, 2.5  μg), NbHsp90.3 (84.5-kDa, 7.5  μg) and 
NbHsp90.3-SAG1HC fusion protein (96-kDa, 9 μg). Each 
group received 4 doses (every 15  days) of each protein 
or PBS control. One day before immunizing, mice were 
bled from the tail vein and sera were stored at -20 °C until 
analysis.
Antibody titers and isotype determination
Anti-rSAG1m and anti-rNbHsp90.3 antibodies in the 
sera of vaccinated mice were determined by ELISA. 
Briefly, 96-well microtiter plates (Nunc  MaxiSorp™ 
flat-bottom, Thermo Fisher, Waltham, MA, USA) were 
coated overnight at 4  °C with 5  µg/ml of rSAG1m or 
50  µg/ml of TLA  (SAG1TLA). Serial dilutions of mice 
sera were carried out to determine the total IgG (IgGt) 
titer. The cut-off value was defined as the media of pre-
immune sera absorbance values plus three standard devi-
ations. For isotype determination, mice sera were diluted 
1:100. Either goat anti-mouse IgG-horseradish peroxi-
dase conjugated (1:5000) (Sigma-Aldrich, St. Louis, MO, 
USA), rat anti-mouse IgG1, IgG2a or IgG2b horseradish 
peroxidase conjugated (1:10000) (Sigma-Aldrich) were 
used as secondary antibodies. Tetramethyl-benzidine 
substrate (TMB; Invitrogen) was added and plates were 
read at 655 nm with an automatic ELISA reader (Synergy 
H1; Bio-Tek, Winooski, VT, USA).
Cytokine analysis
The cytokine production was evaluated in independent 
experiments, either 15  days after the last immunization 
(pre-challenge) or 30 days after challenging with 20 Me49 
tissue cysts (post-challenge). Spleens from 5 immunized 
mice from each group were removed and the splenocytes 
(1.25 × 106 cells/well) were stimulated with either 10 µg/
ml of rSAG1m, rNbHsp90.3 or rGRA4. After 72 h, the 
production of IL-4, IL-10 and IFN-γ in harvested cell-
free supernatants was assessed as previously described by 
Corigliano et al. [19].
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Challenge infection
Two weeks after the last immunization, mice were orally 
challenged with 20 tissue cysts of T. gondii Me49 strain 
as previously described [21]. Mice were observed daily 
for mortality determination. One month after the chal-
lenge, animals were sacrificed, and their brains were 
removed for tissue cyst quantification. Each brain was 
homogenized in 2 ml of PBS by eight passages through a 
21-gage needle [22]. The mean number of cysts per brain 
was determined by observation with an optical micro-
scope, by counting four samples of 20 μl aliquots of each 
homogenized brain [21].
Statistical analysis
Statistical analysis was carried out with Prism 5.0 (Graph-
Pad, San Diego, CA, USA) using one- and two-way analy-
sis of variance (ANOVA). Statistical analysis was carried 
out using Tukey’s multiple comparisons test to compare 




We expressed peptide of Toxoplasma gondii SAG1 from 
 aa221 to  aa319  (SAG1HC). This peptide encloses B- and 
T-cell epitopes [10]. The peptide was cloned in frame 
with Nicotiana benthamiana Hsp90.3 (NbHsp90.3) [18] 
and was expressed and purified from E. coli.
Humoral immune response generated 
by NbHsp90.3‑SAG1HC fusion protein
Mice were intraperitoneal immunized with the 
NbHsp90.3-SAG1HC fusion protein (NbHsp90.3-SAG1HC 
group), SAG1m  (SAG1m group), NbHsp90.3 (NbHsp90.3 
group) or PBS buffer 1× (PBS group). In order to admin-
istrate approximately equimolar quantities of recombi-
nant proteins, the immunization doses for each antigen 
formulation were: SAG1m (34-kDa, 2.5  μg), NbHsp90.3 
(84.5-kDa, 7.5  μg) and NbHsp90.3-SAG1HC fusion pro-
tein (96-kDa, 9 μg) of PBS 1×.
The efficacy of vaccination in immunized mice was 
determined by serological analysis. First, we analyzed 
by Western blot whether the sera from mice immu-
nized with the different formulations were able to recog-
nize SAG1 antigen present in TLA  (SAG1TLA). The sera 
pools from mice immunized with NbHsp90.3-SAG1HC 
fusion protein or SAG1m were able to immunodetect 
 SAG1TLA (Additional file  1: Figure S1). Therefore, we 
used  SAG1TLA and recombinant SAG1m (rSAG1m) in all 
serological analysis. Production of IgG antibodies against 
rSAG1m and  SAG1TLA was evaluated by ELISA 60 days 
after the first immunization. The levels of anti-rSAG1m 
and anti-SAG1TLA total IgG antibodies were strongly 
increased in NbHsp90.3-SAG1HC-immunized mice 
(Fig.  1). In fact, significant differences were observed 
between the NbHsp90.3-SAG1HC group and control 
groups (SAG1m- NbHsp90.3- and PBS-immunized mice) 
(Fig.  1). Therefore, NbHsp90.3-SAG1HC formulation 
Fig. 1 Levels of anti‑SAG1 total IgG antibodies in the sera of C57BL/6 immunized mice. Two weeks after the last immunization, serum samples (8 
mice per group) were collected to analyze IgGt by ELISA with rSAG1m (a) and  SAG1TLA (b) as the bound target. Sera were diluted 1:1000 or 1:100 
for detecting rSAG1m or  SAG1TLA, respectively. Each bar represents the group mean ± SEM. Results represent one of three similar experiments. 
Pre‑immune sera were used as a negative control. a ****P < 0.0001, NbHsp90.3HC vs PBS, NbHsp90.3 and SAG1m groups. b *P < 0.05, NbHsp90.3HC vs 
SAG1m group; ***P < 0.001, NbHsp90.3HC vs PBS and NbHsp90.3 groups. Statistical analysis was performed by one‑way analysis of variance (ANOVA) 
using Tukey’s multiple comparisons test
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elicits a strong humoral response in comparison with 
SAG1m group, suggesting that NbHsp90.3 works as 
an efficient adjuvant to stimulate B-cell epitopes when 
associated to the antigen of interest. In addition, no anti-
rSAG1m or anti-SAGTLA IgGt was detected in the PBS or 
NbHsp90.3 groups (Fig. 1).
To investigate the isotype profile induced after immu-
nization, we evaluated the presence of IgG1, IgG2a and 
IgG2b antibodies in serum samples on day 60, by using 
rSAG1m or  SAG1TLA as the bound targets (Fig.  2). 
All NbHsp90.3-SAG1HC-immunized mice produced 
IgG1 and IgG2a antibodies that were able to recog-
nize rSAG1m but not  SAG1TLA (Fig.  2). In addition, 
NbHsp90.3-SAG1HC-immunized mice produced high 
levels of anti-SAG1TLA IgG2b antibody isotype, whereas 
SAG1m-immunized mice showed a predominant specific 
IgG1 response against  SAG1TLA. Furthermore, higher 
levels of anti-rSAG1m IgG2b antibodies were observed 
in NbHsp90.3 and SAG1m groups respect to PBS group, 
which were not observed when the  SAG1TLA was used as 
the bound target (Fig. 2). This could be due to the shared 
N-terminus sequences for both recombinant proteins.
Cellular immune response generated 
by NbHsp90.3‑SAG1HC fusion protein
To evaluate the cytokine response profile, spleno-
cytes from vaccinated mice were stimulated with either 
rSAG1m or rNbHsp90.3 and the amounts of cytokine 
production (IFN-γ, IL-4 and IL-10) in different groups 
were measured. As shown in Fig.  3a, NbHsp90.3-
SAG1HC-immunized mice generated a significantly 
higher level of IFN-γ compared with control groups 
(SAG1m-, NbHsp90.3- and PBS-immunized mice). 
Meanwhile, SAG1m and NHsp90.3 groups produced 
a significantly higher level of IL-10 compared with 
NHsp90.3-SAG1HC-immunized mice (Fig.  3b). IL-4 was 
not detected in any group (data not shown).
Parasite load and humoral and cellular response after T. 
gondii infection
To assess the effect on parasite load against T. gondii 
infection, two weeks after the vaccination schedule was 
completed, immunized mice were orally challenged and 
the number of T. gondii brain cysts was analyzed one 
month later. All mice survived for 30 days. The behavior 
of NbHsp90.3-SAG1HC-immunized mice was apparently 
normal, while SAG1m-, NbHsp90.3- and PBS-immu-
nized mice exhibited lack of movement and a general 
aspect indicating illness. While the brain cyst loads in 
SAG1- and NbHsp90.3-immunized mice were not sig-
nificantly lower compared to PBS-immunized mice, 
the NbHsp90.3-SAG1HC-immunized mice presented a 
significant reduction in the cyst load (56%) when com-
pared to control groups (SAG1m-, NbHsp90.3- and PBS-
immunized mice) (Fig. 4a). In addition, we evaluated the 
humoral immune response in the chronic phase of T. gon-
dii infection (Fig. 4b, c). Thirty days after the challenge, 
the levels of anti-TLA IgGt were significantly increased 
in all groups (Fig.  4b), especially in the NbHsp90.3-
SAG1HC-immunized mice (Fig.  4b). By contrast, high 
levels of anti-rSAG1m IgGt antibodies were detected 
in NbHsp90.3-SAG1HC- and SAG1m-immunized mice, 
while no response was observed in NbHsp90.3 and PBS 
groups (Fig. 4c). Furthermore, we evaluated the cytokine 
profile in sera from immunized and challenged mice dur-
ing the acute and chronic phases of T. gondii infection (10 
Fig. 2 Analysis of IgG isotype antibodies against SAG1 in the sera of C57BL/6 immunized mice. Two weeks after the immunization schedule was 
completed, serum samples (8 mice per group) were collected and diluted 1:100 to analyze IgG1, IgG2a and IgG2b sub‑classes with rSAG1m (a) or 
 SAG1TLA (b) as the bound target. Each bar represents the group mean ± SEM. Results represent one of three similar experiments. Pre‑immune sera 
were used as a negative control. *P < 0.05; ***P < 0.001; ****P < 0.0001. Statistical analysis was performed by two‑way analysis of variance (ANOVA) 
using Tukey’s multiple comparisons test
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and 30 days after the challenge, respectively). The levels 
of IFN-γ were induced in the acute phase but they were 
significantly diminished in the sera from all mice with 
chronic infection. Actually, no significant differences 
were observed among groups (Fig.  5a). On the other 
hand, IL-10 and IL-4 were undetectable in sera from all 
mice with acute and chronic infection (data not shown). 
In addition, the cytokine profile was analyzed in super-
natant of spleen cell cultures. IL-10, IL-4 and IFN-γ pro-
duction was measured in the supernatants from spleen 
Fig. 3 Cytokine production by spleen cell cultures from C57BL/6 immunized mice. Two weeks after last immunization, splenocytes from 5 mice 
per group were cultured, and the cytokine production in cell supernatants after rSAG1 stimulation was measured by ELISA. Values for IFN‑γ (a) 
and IL‑10 (b) at 72 h are expressed as mean ± SEM. Results represent one of two similar experiments. IFN‑γ: ***P < 0.001 NbHsp90.3‑SAG1HC vs PBS, 
NbHsp90.3 and SAG1m groups. IL‑10: *P < 0.05, NbHsp90.3 vs NbHsp90.3‑SAG1HC group; **P < 0.01, NbHsp90.3 vs PBS group; ***P < 0.001, SAG1m 
vs NbHsp90.3‑SAG1HC group; ****P < 0.0001 SAG1m vs PBS group. Statistical analysis was performed by two‑way analysis of variance (ANOVA) using 
Tukey’s multiple comparisons test
Fig. 4 Post‑challenge analysis in C57BL/6 immunized mice after T. gondii infection. a Protection against chronic T. gondii infection in C57BL/6 
immunized mice. Two weeks after the last immunization, mice were orally challenged with 20 tissue cysts of ME49 T. gondii strain (sub‑lethal 
dose). Thirty days after the infection, mice were sacrificed, and their brains were removed for cyst load determination. Each bar represents the 
group mean ± SEM. Results represent one of three similar experiments. **P < 0.01, NbHsp90.3‑SAG1HC vs NbHsp90.3 group; ****P < 0.0001, 
NbHsp90.3‑SAG1HC vs PBS and SAG1m groups. b, c Antigen‑specific antibodies in sera from C57BL/6 immunized mice with chronic T. gondii 
infection. Thirty days after mice were orally challenged with 20 tissue cysts of ME49 T. gondii strain (sub‑lethal dose), serum samples (8 mice per 
group) were obtained and IgGt was determined by ELISA with TLA (b) or rSAG1m (c) as the bound targets (sera were diluted 1:16,000 and 1:1000, 
respectively). Each bar represents the group mean ± SEM. Results represent one of two similar experiments. b ***P < 0.001, NbHsp90.3‑SAG1HC 
vs PBS, NbHsp90.3 and SAG1m groups. c **P < 0.01, NbHsp90.3‑SAG1HC vs SAG1m group; ***P < 0.001, NbHsp90.3‑SAG1HC vs PBS and NbHsp90.3 
groups. Pre‑immune sera were used as a negative control. Statistical analysis was performed by one‑way analysis of variance (ANOVA) using Tukey’s 
multiple comparisons test
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cells culture of immunized mice in the chronic phase of 
T. gondii infection. Splenocytes were stimulated in vitro 
with rSAG1m and recombinant GRA4 (rGRA4) (Fig. 5b). 
The stimulation with rGRA4 was carried out in order to 
distinguish the cellular response induced by the T. gondii 
challenge from the cellular response induced by the vac-
cination and the challenge. As expected, after the chal-
lenge, IFN-γ levels were strongly induced in all groups 
when spleen cells were stimulated with rGRA4 (Fig. 5b), 
while IL-10 was not secreted (Fig.  5c). On the other 
hand, the spleen cells from SAG1m- and NbHsp90.3-
SAG1HC-immunized mice stimulated with rSAG1m 
showed different cytokine profile production (Fig.  5b, 
c). While, the levels of IFN-γ were significantly induced 
in the NbHsp90.3-SAG1HC-immunized mice (Fig.  5b), 
IL-10 was only secreted by splenocytes from SAG1m-
immunized mice (Fig.  5c). Notably, splenocytes from 
NbHsp90.3- and PBS-immunized mice stimulated with 
rSAG1m did not show an increase of any of the analyzed 
cytokines. Finally, IL-4 was not secreted by spleen cells 
of any of the groups stimulated with either rGRA4 or 
rSAG1m (data not shown).
Discussion
Several Hsp90s from different organisms, in particu-
lar Gp96, are being studied as promising adjuvants to 
enhance innate and adaptive immune responses, espe-
cially as potent T cell activators for designing vaccines 
against infectious diseases [19, 23–28]. According to 
these properties, Hsp90s have been explored as adju-
vants for enhancing vaccine potency [28–30]. The most 
useful, simple and feasible strategy employed is to cova-
lently link the desired antigen to Hsp90. In previous stud-
ies, it was demonstrated that immunization with Hsp90 
from Leishmania infantum (LiHsp83) fused to a reporter 
antigen (MBP-LiHsp83) or a T. gondii Rop2 antigen 
(Rop2-LiHsp83), generated mainly IgG2a isotype anti-
bodies inferring the involvement of an immune response 
mediated by Th1 cells [23, 24, 31]. Like other Hsp90s, 
the Hsp90.3 isoform from Nicotiana benthamiana 
(NbHsp90.3) is also considered a promising adjuvant with 
the advantage that NbHsp90.3 comes from a non-patho-
genic source and it can be used for any pathogen-asso-
ciated antigens, whereas LiHsp83 could interfere with 
antigens from other pathogens such as trypanosomatids. 
In agreement with this, we previously demonstrated that 
BALB/c mice immunized with MBP-NbHsp90.3 were 
able to elicit a Th1 immune response against MBP [19]. 
Since analysis with generic antigens will not necessar-
ily reproduce the immune response against microbial- 
or parasitic-derived antigens, we aimed to evaluate the 
potential of NbHsp90.3 as a carrier/adjuvant of a peptide 
from T. gondii SAG1 protein.
SAG1 is considered an important antigen for the devel-
opment of effective diagnostic tests or subunit vaccines 
[6]. Significant progress has been made towards charac-
terization of its immunogenicity and a significant amount 
of information is available to date on the different anti-
genic regions related to T- or B-cell responses [10, 12, 
32–34]. In the present study, we analyzed both humoral 
and cellular immune responses induced by NbHsp90.3 
covalently linked to  SAG1HC (a peptide that contains a 
T- and B-cell epitopes) [10]. NbHsp90.3, SAG1m or PBS 
were defined as control groups and the experiments were 
carried out in the murine model.
Humoral response analysis showed that NbHsp90.3-
SAG1HC-immunized mice induced a high production of 
specific-antibodies that were able to recognize rSAG1m 
and also  SAG1TLA. Sera from NbHsp90.3-SAG1HC-
immunized mice showed a significant increase of anti-
rSAG1m IgG2a and IgG2b antibody isotypes and only 
anti-SAG1TLA IgG2b antibodies. This finding suggests 
that the B-cell epitope present in the  SAG1HC peptide 
would generate antibodies which are able to distinguish 
rSAG1m from  SAG1TLA. Another interesting result is 
that the SAG1-immunized mice showed a significative 
increase of the anti-SAG1TLA IgG1 levels, suggesting 
that humoral immune response induced by NbHsp90.3-
SAG1HC formulation is addressed towards a Th1 profile 
when the antigenic peptide is carried by NbHsp90.3. 
These outcomes are consistent with those found by 
Corigliano et  al. [19]. However, it must be noted that 
while in the present study  SAG1HC is fused to the 
C-terminus of NbHsp90.3, the carried protein was 
fused to the N-terminus in Corigliano et al. [19]. There-
fore, the adjuvant properties present in NbHsp90.3 will 
be maintained independently where the carrier protein 
is situated. It is also worthy of mention that in order 
to trigger a specific humoral immune response against 
the carried antigen, it is not necessary to fuse the com-
plete protein of interest to NbHsp90.3, but only those 
epitopes with antigenic capacity.
As cytokines play an important role in the protec-
tion against T. gondii infection, we assessed their pro-
duction. Our previous studies showed that NbHsp90.3 
elicited a high production of IFN-γ when used as adju-
vant [19]. It is important to note that IFN-γ is a key 
mediator in the mechanisms of T. gondii resistance 
and plays an important role in protecting hosts dur-
ing both acute and chronic phases of toxoplasmosis 
[35–37]. In this study, we observed that splenocytes 
from NbHsp90.3-SAG1HC-immunized mice produced 
the highest amounts of IFN-γ when stimulated with 
rSAG1m. These results confirm that the presence of the 
selected T- and B-cell epitopes of SAG1 is enough to 
elicit a Th1 immune response when they are fused to 
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Fig. 5 Cytokine detection in spleen cell cultures and sera from C57BL/6 immunized mice after T. gondii infection. a Values of IFN‑γ in serum samples 
(5 mice per group) at 10 days (acute infection) and 30 days (chronic infection) after mice were orally challenged with 20 tissue cysts of ME49 T. 
gondii strain (sub‑lethal dose). Sera were diluted 1:10 and IFN‑γ was measured by ELISA. Values of IFN‑γ (b) and IL‑10 (c) in supernatants of spleen 
cell cultures in the chronic infection. Splenocytes from 5 mice per group were cultured and stimulated with either rSAG1 or rGRA4. Cytokine was 
measured in cell supernatants after 72 h of culture by ELISA. Each bar represents the group mean ± SEM. Results represent one of two similar 
experiments. IFN‑γ: *P < 0.05, NbHsp90.3‑SAG1HC vs PBS, NbHsp90.3 and SAG1m groups. IL‑10: ***P < 0.001, NbHsp90.3‑SAG1HC vs PBS, NbHsp90.3 
and NbHsp90.3‑SAG1HC groups. Statistical analysis was performed by two‑way analysis of variance (ANOVA) using Tukey’s multiple comparisons test
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NbHsp90.3. On the other hand, it is generally assumed 
that IL-10 production correlates with a Th2 T-cell 
response [38]. In our study, high levels of IL-10 were 
elicited by spleen cells from mice of control groups 
(SAG1m and NbHsp90.3 groups). Actually, the high 
levels of IL-10 could explain the absence of IFN-γ in the 
SAG1m- and NbHsp90.30-immunized mice. According 
to these results, the immunization with SAG1m alone 
would induce a Th2 immune response with a produc-
tion of IgG1 antibodies and IL-10 secretion. In fact, 
several lineal and conformational B-cell epitopes have 
been identified in SAG1 protein, most of them localized 
in the N-terminus region [39]; thus, it is expected that 
immunization with SAG1m alone would induce a Th2 
immune response.
As the main goal of vaccination is the stimulation of a 
protective immune response against a defined pathogen, 
immunized mice were infected with T. gondii. In order 
to assess the protective immunity against T. gondii infec-
tion, the humoral and cellular immune responses were 
analyzed after the challenge. Interestingly, while anti-
bodies from NbHsp90.3-SAG1HC-immunized mice were 
able to respond to rSAG1m and  SAG1TLA, the antibod-
ies generated after the infection were unable to react 
with rSAG1m, but they did with the TLA extract. This 
could be explained by the posttranslational modification 
that takes place to the native SAG1 into the parasite [32] 
which could contribute in modifying the conformational 
profile of epitopes of both proteins. Similar results were 
observed by Sánchez et al. [40]. The authors showed that 
sera from mice infected with T. gondii were unable to 
recognize the recombinant TgPI-1 protein [40]. Taken 
together, these results suggest that rSAG1m y  SAG1TLA 
carried dissimilar epitopes that make it possible to differ-
entiate between vaccinated and infected mice.
On the other hand, the analysis of cytokines after the 
challenge in the chronic phase of T. gondii infection 
showed that rGRA4-stimulated spleen cells enhanced 
a high production of IFN-γ without secretion of either 
IL-10 or IL-4, indicating the T. gondii infection elicited 
a strong adaptative Th1 T cell immune response in mice 
from all groups. Only rSAG1m-stimulated spleen cells 
from NbHsp90.3-SAG1HC group also showed high pro-
duction of IFN-γ in agreement with what was observed 
before the challenge. In addition, SAG1m group triggered 
a Th2 adaptative immune response against rSAG1m 
indicating that T. gondii infection did not modify the 
cytokine profile against the SAG1m antigen elicited by 
the immunization. Taken together these results indi-
cate that the NbHsp90.3 protein not only enhances cell 
memory response against the carried antigen but also 
modulates the response towards a Th1 profile in the 
immunized mice, which could be responsible for the 
conferred immune protection against T. gondii infection. 
More importantly, NbHsp90.3-SAG1HC-immunized mice 
showed a significant reduction in the parasitic load (56%) 
with respect to the other groups concurrently in agree-
ment with the cellular and humoral response observed in 
this group. Therefore, the capability of NbHsp90.3-adju-
vanted vaccines to induce memory T cells can respond 
more rapidly to challenge and provide a long-term pro-
tective anti-T. gondii immunity. Although the percentage 
of cyst load reduction is comparable to others immunized 
with recombinant proteins [40–44], we emphasize that 
in the NbHsp90.3-SAG1HC group no exogenous adju-
vant was added. In summary, these results indicate that 
the cellular and humoral immune responses induced by 
NbHsp90.3-SAG1HC formulation are addressed towards 
a Th1 immune profile with a production of IFN-γ, IgG2a 
and IgG2b antibodies against the carried antigen. We 
demonstrated the ability of NbHsp90.3 as an excellent 
adjuvant that modulates the immune response against T. 
gondii antigens in an appropriate manner.
Conclusions
In the present study we validated the use of NbHsp90.3 
as an adjuvant in a murine model. We developed and 
validated a vaccine formulation which, to our knowl-
edge, for the first time includes the NbHsp90.3 pro-
tein covalently fused to a peptide from T. gondii SAG1 
protein that contains T- and B-cell epitopes. We also 
demonstrated that NbHsp90.3 enhances a humoral 
and cell- mediated immune response along with Th1 
cytokine production. After the challenge, mice vacci-
nated with NbHsp90.3-SAG1HC exhibited a partial pro-
tection against the T. gondii infection which correlated 
with the induction of the memory immune response. In 
conclusion, NbHsp90.3 is an attractive adjuvant to be 
incorporated in vaccine formulations that require the 
generation of a Th1 profile along with a T-cell mediated 
response to confer immunity.
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